SKYE Skye Bioscience Inc
Price (delayed)
$1.43
Market cap
$44.29M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
-$23.67M
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I
Highlights
SKYE's EPS has surged by 86% year-on-year
The company's quick ratio rose by 16% QoQ
Skye Bioscience's debt has surged by 139% QoQ but it has shrunk by 90% YoY
Skye Bioscience's net income has increased by 29% YoY but it has decreased by 25% QoQ
The equity has contracted by 10% from the previous quarter
Key stats
What are the main financial stats of SKYE
Market
Valuations
Earnings
Shares outstanding
30.97M
Market cap
$44.29M
Enterprise value
-$23.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$30.19M
Net income
-$26.57M
EBIT
-$25.81M
EBITDA
-$25.51M
Free cash flow
-$26.84M
Per share
Balance sheet
Liquidity
EPS
-$0.73
EPS diluted
-$0.73
Free cash flow per share
-$0.74
Book value per share
$2.25
Revenue per share
$0
TBVPS
$1.99
Total assets
$72.76M
Total liabilities
$4.61M
Debt
$455,590
Equity
$68.15M
Working capital
$66.49M
Debt to equity
0.01
Current ratio
16.32
Quick ratio
15.77
Net debt/EBITDA
2.66
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.6%
Return on equity
-35.9%
Return on invested capital
N/A
Return on capital employed
-37.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SKYE stock price
How has the Skye Bioscience stock price performed over time
Intraday
2.14%
1 week
-37.83%
1 month
-49.82%
1 year
N/A
YTD
-49.47%
QTD
-10.06%
Financial performance
How have Skye Bioscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.19M
Net income
-$26.57M
Gross margin
N/A
Net margin
N/A
Skye Bioscience's net income has increased by 29% YoY but it has decreased by 25% QoQ
SKYE's operating income is down by 28% from the previous quarter but it is up by 13% YoY
Growth
What is Skye Bioscience's growth rate over time
Valuation
What is Skye Bioscience stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SKYE's EPS has surged by 86% year-on-year
The equity has contracted by 10% from the previous quarter
Efficiency
How efficient is Skye Bioscience business performance
The ROA has soared by 93% YoY but it has decreased by 2.6% from the previous quarter
The company's return on equity rose by 4.8% QoQ
Dividends
What is SKYE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SKYE.
Financial health
How did Skye Bioscience financials performed over time
The company's total liabilities has shrunk by 67% YoY and by 20% QoQ
The company's quick ratio rose by 16% QoQ
Skye Bioscience's debt is 99% lower than its equity
Skye Bioscience's debt has surged by 139% QoQ but it has shrunk by 90% YoY
The debt to equity has soared by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.